Skip to main content
NCBI home page
Bulletin of the New York Academy of Medicine logoLink to Bulletin of the New York Academy of Medicine
. 1982 Nov;58(8):696–710.

The third generation cephalosporins.

B Farber, R C Moellering Jr
PMCID: PMC1805373  PMID: 6762896

Full text

PDF
696

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams H. G., Stilwell G. A., Turck M. In vitro evaluation of cefoxitin and cefamandole. Antimicrob Agents Chemother. 1976 Jun;9(6):1019–1024. doi: 10.1128/aac.9.6.1019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barza M., Tally F. P., Jacobus N. V., Gorbach S. L. In vitro activity of LY127935. Antimicrob Agents Chemother. 1979 Sep;16(3):287–292. doi: 10.1128/aac.16.3.287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bolton W. K., Scheld W. M., Spyker D. A., Overby T. L., Sande M. A. Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction. Antimicrob Agents Chemother. 1980 Dec;18(6):933–938. doi: 10.1128/aac.18.6.933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cooper R. H., Savitch C. B., Joseph W. P., Mills J. Evaluation of ceforanide as treatment for staphylococcal and streptococcal endocarditis. Antimicrob Agents Chemother. 1981 Feb;19(2):256–259. doi: 10.1128/aac.19.2.256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fu K. P., Aswapokee P., Ho I., Matthijssen C., Neu H. C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother. 1979 Nov;16(5):592–597. doi: 10.1128/aac.16.5.592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fu K. P., Neu H. C. Antibacteroides and beta-lactamase inhibitory activities of moxalactam. J Antimicrob Chemother. 1981 Oct;8(4):337–341. doi: 10.1093/jac/8.4.337. [DOI] [PubMed] [Google Scholar]
  7. Georgopapadakou N. H., Liu F. Y. Binding of beta-lactam antibiotics to penicillin-binding proteins of Staphylococcus aureus and Streptococcus faecalis: relation to antibacterial activity. Antimicrob Agents Chemother. 1980 Nov;18(5):834–836. doi: 10.1128/aac.18.5.834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ginsburg C. M., McCracken G. H., Jr Cefaclor and cefadroxil: a commentary on their properties and possible indications for use in pediatrics. J Pediatr. 1980 Feb;96(2):340–342. doi: 10.1016/s0022-3476(80)80843-2. [DOI] [PubMed] [Google Scholar]
  9. Godfrey A. J., Bryan L. E., Rabin H. R. beta-Lactam-resistant Pseudomonas aeruginosa with modified penicillin-binding proteins emerging during cystic fibrosis treatment. Antimicrob Agents Chemother. 1981 May;19(5):705–711. doi: 10.1128/aac.19.5.705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Griffith R. S., Black H. R., Brier G. L., Wolny J. D. Cefamandole: in vitro and clinical pharmacokinetics. Antimicrob Agents Chemother. 1976 Nov;10(5):814–823. doi: 10.1128/aac.10.5.814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jorgensen J. H., Alexander G. A. Comparative activities of selected beta-lactam antibiotics against Haemophilus influenzae. Antimicrob Agents Chemother. 1978 Feb;13(2):342–343. doi: 10.1128/aac.13.2.342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kammer R. B., Preston D. A., Turner J. R., Hawley L. C. Rapid detection of ampicillin-resistant Haemophilus influenzae and their susceptibility to sixteen antibiotics. Antimicrob Agents Chemother. 1975 Jul;8(1):91–94. doi: 10.1128/aac.8.1.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Khaleeli M., Giorgio A. J. Defective platelet function after cephalosporin administration. Blood. 1976 Nov;48(5):791–792. [PubMed] [Google Scholar]
  14. Komatsu Y., Murakami K., Nishikawa T. Penetration of moxalactam into its target proteins in Escherichia coli K-12: comparison of a highly moxalactam resistant mutant with its parent strain. Antimicrob Agents Chemother. 1981 Nov;20(5):613–619. doi: 10.1128/aac.20.5.613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lode H., Kemmerich B., Koeppe P., Belmega D., Jendroschek H. Comparative pharmacokinetics of cefoperazone and cefotaxime. Clin Ther. 1980;3(Spec Issue):80–88. [PubMed] [Google Scholar]
  16. Moellering R. C., Jr, Dray M., Kunz L. J. Susceptibility of clinical isolates of bacteria to cefoxitin and cephalothin. Antimicrob Agents Chemother. 1974 Sep;6(3):320–323. doi: 10.1128/aac.6.3.320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Moellering R. C., Jr, Swartz M. N. Drug therapy: The newer cephalosporins. N Engl J Med. 1976 Jan 1;294(1):24–28. doi: 10.1056/NEJM197601012940106. [DOI] [PubMed] [Google Scholar]
  18. Murray B. E., Moellering R. C., Jr Cephalosporins. Annu Rev Med. 1981;32:559–581. doi: 10.1146/annurev.me.32.020181.003015. [DOI] [PubMed] [Google Scholar]
  19. Murray P. R., Christman J. L., Medoff G. In vitro activity of HR 756, a new cephalosporin, against Neisseria gonorrhoeae. Antimicrob Agents Chemother. 1979 Mar;15(3):452–454. doi: 10.1128/aac.15.3.452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Neu H. C. Bacteremia in the 1980s with special reference to the role of cefotaxime. Clin Ther. 1981;4 (Suppl A):55–66. [PubMed] [Google Scholar]
  21. Ott J. L., Turner J. R., Mahoney D. F. Lack of correlation between beta-lactamase production and susceptibility to cefamandole or cefoxitin among spontaneous mutants of Enterobacteriaceae. Antimicrob Agents Chemother. 1979 Jan;15(1):14–19. doi: 10.1128/aac.15.1.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ott J. L., Turner J. R., Mahoney D. F. Lack of correlation between beta-lactamase production and susceptibility to cefamandole or cefoxitin among spontaneous mutants of Enterobacteriaceae. Antimicrob Agents Chemother. 1979 Jan;15(1):14–19. doi: 10.1128/aac.15.1.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Smith C. R. Considerations regarding clinical safety and tolerability of antibiotics in serious and nosocomial infections. Clin Ther. 1981;4 (Suppl A):133–145. [PubMed] [Google Scholar]
  24. Sosna J. P., Murray P. R., Medoff G. Comparison of the in vitro activities of HR756 with cephalothin, cefoxitin, and cefamandole. Antimicrob Agents Chemother. 1978 Dec;14(6):876–879. doi: 10.1128/aac.14.6.876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Stapley E. O., Birnbaum J., Miller A. K., Wallick H., Hendlin D., Woodruff H. B. Cefoxitin and cephamycins: microbiological studies. Rev Infect Dis. 1979 Jan-Feb;1(1):73–89. doi: 10.1093/clinids/1.1.73. [DOI] [PubMed] [Google Scholar]
  26. Stone H. H., Geheber C. E., Kolb L. D., Dunlop W. E. Clinical comparison of cefotaxime versus the combination of gentamicin plus clindamycin in the treatment of peritonitis and similar polymicrobial soft-tissue surgical sepsis. Clin Ther. 1981;4 (Suppl A):67–80. [PubMed] [Google Scholar]
  27. Swartz M. N. Intraventricular use of aminoglycosides in the treatment of gram-negative bacillary meningitis: conflicting views. J Infect Dis. 1981 Feb;143(2):293–296. doi: 10.1093/infdis/143.2.293. [DOI] [PubMed] [Google Scholar]
  28. Tally F. P., Jacobus N. V., Bartlett J. G., Gorbach S. L. Susceptibility of anaerobes to cefoxitin and other cephalosporins. Antimicrob Agents Chemother. 1975 Feb;7(2):128–132. doi: 10.1128/aac.7.2.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Tomasz A. From penicillin-binding proteins to the lysis and death of bacteria: a 1979 view. Rev Infect Dis. 1979 May-Jun;1(3):434–467. doi: 10.1093/clinids/1.3.434. [DOI] [PubMed] [Google Scholar]
  30. Wade J. C., Smith C. R., Petty B. G., Lipsky J. J., Conrad G., Ellner J., Lietman P. S. Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside. Lancet. 1978 Sep 16;2(8090):604–606. doi: 10.1016/s0140-6736(78)92825-8. [DOI] [PubMed] [Google Scholar]
  31. Washington J. A. The in vitro spectrum of the cephalosporins. Mayo Clin Proc. 1976 Apr;51(4):237–250. [PubMed] [Google Scholar]
  32. Weaver S. S., LeBlanc B. M., Bodey G. P. In vitro studies of 1-oxacephalosporin (LY 127935), a new beta-lactam antibiotic. Antimicrob Agents Chemother. 1980 Jan;17(1):92–95. doi: 10.1128/aac.17.1.92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Wise R., Baker S., Wright N., Livingston R. The pharmacokinetics of LY127935, a broad spectrum oxa-beta-lactam. J Antimicrob Chemother. 1980 May;6(3):319–322. doi: 10.1093/jac/6.3.319. [DOI] [PubMed] [Google Scholar]
  34. Wise R., Wright N., Wills P. J. Pharmacology of cefotaxime and its desacetyl metabolite in renal and hepatic disease. Antimicrob Agents Chemother. 1981 Apr;19(4):526–531. doi: 10.1128/aac.19.4.526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Yabuuchi E., Ito T., Tanimura E., Yamamoto N., Ohyama A. In vitro antimicrobial activity of ceftizoxime against glucose-nonfermentative gram-negative rods. Antimicrob Agents Chemother. 1981 Jul;20(1):136–139. doi: 10.1128/aac.20.1.136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Yu V. L. Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic. Ann Intern Med. 1981 Jun;94(6):784–785. doi: 10.7326/0003-4819-94-6-784. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the New York Academy of Medicine are provided here courtesy of New York Academy of Medicine

RESOURCES